Roche Holding AG is trading 2.9% down now at $317.10 even as investors digest encouraging oncology news regarding its lymphoma treatment pipeline.
- The FDA has accepted a supplemental Biologics License Application for a chemo-free Lunsumio + Polivy combination, which demonstrated a 59% risk reduction in relapsed or refractory large B-cell lymphoma compared to standard care.
- The stock's decline contrasts with broadly higher equity markets, suggesting the move may be driven by profit-taking or sector rotation rather than negative company-specific developments.